Innovation at Penn
Browse Penn-owned technologies available for licensing.
Search Results - irfan+asangani
Therapy overcoming resistance of refractory prostate cancer
Inhibition of cyclin-dependent-kinase 7 (CDK7) for treatment of refractory castration-resistant prostate cancer (CRPC) through reduction of androgen receptor transcriptional activity. Technology Overview: Prostate cancer is the most common non-cutaneous malignancy, and the second leading cause of cancer-related death in men of the western world....
Therapeutics & Vaccines
© 2021. All Rights Reserved. Powered by